Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer

被引:0
作者
Nicoletto, Maria Ornella [1 ]
Baldoni, Alessandra [2 ]
Cavallin, Francesco
Grego, Andrea [3 ]
Falci, Cristina [4 ]
Nardin, Margherita [5 ]
Mammano, Enzo [6 ]
Lai, Eleonora [4 ]
Torri, Valter [7 ]
机构
[1] Ist Oncol Veneto IRCCS, Med Oncol 2, Via Gattamelata 64, I-35121 Padua, Italy
[2] Mirano Hosp, Dept Med Oncol, AULSS Serenissima 3, Mirano, VE, Italy
[3] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[4] Ist Oncol Veneto IRCCS, Med Oncol 2, Padua, Italy
[5] Ist Oncol Veneto IRCCS, Radiol Dept, Padua, Italy
[6] Osped St Antonio, Dept Surg, Padua, Italy
[7] Ist Ric Farmacol Mario Negri IRCCS, Lab Methodol Clin Res, Milan, Italy
关键词
BRCA mutated; PARP inhibitors; oxaliplatin; pegylated liposomal doxorubicin; platinum-sensitive epithelial ovarian cancer; PEGYLATED LIPOSOMAL DOXORUBICIN; RECURRENT EPITHELIAL OVARIAN; DOUBLE-BLIND; PHASE-II; MAINTENANCE THERAPY; OPEN-LABEL; OLAPARIB; MULTICENTER; BEVACIZUMAB; CHEMOTHERAPY;
D O I
10.1177/17588359231173181
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:The use of PARP inhibitor (PARPi) has shown a considerable benefit in progression-free survival (PFS) in relapsed, platinum-sensitive epithelial ovarian cancer (OC). Objective:Our study aimed to investigate the impact of the last platinum-based chemotherapy treatment in response to PARPi. Design:Retrospective cohort study. Patients and methods:The study involved 96 consecutive, pretreated, platinum-sensitive advanced OC patients. Demographics and clinical data were retrieved from clinical records. PFS and overall survival (OS) were calculated from the start of PARPi. Results:Germline BRCA mutation was investigated in all cases. Platinum-based chemotherapy before PARPi maintenance therapy included pegylated liposomal doxorubicin-oxaliplatin (PLD-Ox) in 46 patients (48%) and other platinum-based chemotherapy in 50 patients (52%). During a median follow-up of 22 months from the beginning of PARPi therapy, 57 patients relapsed (median PFS: 12 months) and 64 patients died (median OS: 23 months). During multivariable analysis, receiving PLD-Ox before PARPi was associated with improved PFS [hazard ratio (HR): 0.46, 95% CI: 0.26-0.82] and OS (HR: 0.48, 95% CI: 0.27-0.83). In 36 BRCA-mutated patients, PLD-Ox was associated with improved PFS (2-year PFS: 70.0% versus 25.0%, p = 0.02). Conclusion:Receiving PLD-Ox before PARPi may improve prognosis in platinum-sensitive advanced OC patients and may provide advantages in the BRCA-mutated subgroup.
引用
收藏
页数:10
相关论文
共 40 条
[11]   Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin [J].
Evers, Bastiaan ;
Drost, Rinske ;
Schut, Eva ;
de Bruin, Michiel ;
van der Burg, Eline ;
Derksen, Patrick W. B. ;
Holstege, Henne ;
Liu, Xiaoling ;
van Drunen, Ellen ;
Beverloo, H. Berna ;
Smith, Graeme C. M. ;
Martin, Niall M. B. ;
Lau, Alan ;
O'Connor, Mark J. ;
Jonkers, Jos .
CLINICAL CANCER RESEARCH, 2008, 14 (12) :3916-3925
[12]   Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].
Fong, Peter C. ;
Boss, David S. ;
Yap, Timothy A. ;
Tutt, Andrew ;
Wu, Peijun ;
Mergui-Roelvink, Marja ;
Mortimer, Peter ;
Swaisland, Helen ;
Lau, Alan ;
O'Connor, Mark J. ;
Ashworth, Alan ;
Carmichael, James ;
Kaye, Stan B. ;
Schellens, Jan H. M. ;
de Bono, Johann S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134
[13]   Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study [J].
Gelmon, Karen A. ;
Tischkowitz, Marc ;
Mackay, Helen ;
Swenerton, Kenneth ;
Robidoux, Andre ;
Tonkin, Katia ;
Hirte, Hal ;
Huntsman, David ;
Clemons, Mark ;
Gilks, Blake ;
Yerushalmi, Rinat ;
Macpherson, Euan ;
Carmichael, James ;
Oza, Amit .
LANCET ONCOLOGY, 2011, 12 (09) :852-861
[14]   Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer [J].
Gonzalez-Martin, A. ;
Pothuri, B. ;
Vergote, I. ;
DePont Christensen, R. ;
Graybill, W. ;
Mirza, M. R. ;
McCormick, C. ;
Lorusso, D. ;
Hoskins, P. ;
Freyer, G. ;
Baumann, K. ;
Jardon, K. ;
Redondo, A. ;
Moore, R. G. ;
Vulsteke, C. ;
O'Cearbhaill, R. E. ;
Lund, B. ;
Backes, F. ;
Barretina-Ginesta, P. ;
Haggerty, A. F. ;
Rubio-Perez, M. J. ;
Shahin, M. S. ;
Mangili, G. ;
Bradley, W. H. ;
Bruchim, I. ;
Sun, K. ;
Malinowska, I. A. ;
Li, Y. ;
Gupta, D. ;
Monk, B. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2391-2402
[15]   Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors [J].
Jones, Philip ;
Altamura, Sergio ;
Boueres, Julia ;
Ferrigno, Federica ;
Fonsi, Massimiliano ;
Giomini, Claudia ;
Lamartina, Stefania ;
Monteagudo, Edith ;
Ontoria, Jesus M. ;
Orsale, Maria Vittoria ;
Palumbi, Maria Cecilia ;
Pesci, Silvia ;
Roscilli, Giuseppe ;
Scarpelli, Rita ;
Schultz-Fademrecht, Carsten ;
Toniatti, Carlo ;
Rowley, Michael .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) :7170-7185
[16]   Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [J].
Kaufman, Bella ;
Shapira-Frommer, Ronnie ;
Schmutzler, Rita K. ;
Audeh, M. William ;
Friedlander, Michael ;
Balmana, Judith ;
Mitchell, Gillian ;
Fried, Georgeta ;
Stemmer, Salomon M. ;
Hubert, Ayala ;
Rosengarten, Ora ;
Steiner, Mariana ;
Loman, Niklas ;
Bowen, Karin ;
Fielding, Anitra ;
Domchek, Susan M. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :244-250
[17]   Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer [J].
Kaye, Stan B. ;
Lubinski, Jan ;
Matulonis, Ursula ;
Ang, Joo Ern ;
Gourley, Charlie ;
Karlan, Beth Y. ;
Amnon, Amit ;
Bell-McGuinn, Katherine M. ;
Chen, Lee-May ;
Friedlander, Michael ;
Safra, Tamar ;
Vergote, Ignace ;
Wickens, Mark ;
Lowe, Elizabeth S. ;
Carmichael, James ;
Kaufman, Bella .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) :372-379
[18]   Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial [J].
Ledermann, Jonathan ;
Harter, Philipp ;
Gourley, Charlie ;
Friedlander, Michael ;
Vergote, Ignace ;
Rustin, Gordon ;
Scott, Clare L. ;
Meier, Werner ;
Shapira-Frommer, Ronnie ;
Safra, Tamar ;
Matei, Daniela ;
Fielding, Anitra ;
Spencer, Stuart ;
Dougherty, Brian ;
Orr, Maria ;
Hodgson, Darren ;
Barrett, J. Carl ;
Matulonis, Ursula .
LANCET ONCOLOGY, 2014, 15 (08) :852-861
[19]   Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial [J].
Ledermann, Jonathan A. ;
Embleton, Andrew C. ;
Raja, Fharat ;
Perren, Timothy J. ;
Jayson, Gordon C. ;
Rustin, Gordon J. S. ;
Kaye, Stan B. ;
Hirte, Hal ;
Eisenhauer, Elizabeth ;
Vaughan, Michelle ;
Friedlander, Michael ;
Gonzalez-Martin, Antonio ;
Stark, Daniel ;
Clark, Elizabeth ;
Farrelly, Laura ;
Swart, Ann Marie ;
Cook, Adrian ;
Kaplan, Richard S. ;
Parmar, Mahesh K. B. .
LANCET, 2016, 387 (10023) :1066-1074
[20]   Epithelial ovarian cancer [J].
Lheureux, Stephanie ;
Gourley, Charlie ;
Vergote, Ignace ;
Oza, Amit M. .
LANCET, 2019, 393 (10177) :1240-1253